Brought to you by 
Series B round brings in $38.5mm for Otonomy
31 Aug 2010
Executive Summary
Three months after closing its $10mm Series A venture round, Otonomy Inc. (therapeutics for ear disorders) has raised $38.5mm through its Series B. Novo Ventures and RiverVest Venture Partners co-led the financing and were joined by fellow new backers Domain Associates and TPG Biotech (all contribute one board member) and current shareholder Avalon Ventures. Otonomy will use the funds to continue developing Phase Ib OTO104 for Meniere's disease and preclinical OTO203 for otitis media.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round brings in $38.5mm for Otonomy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice